Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Finally we argue that the estimated penetrance of CI calcula
2023-08-30

Finally, we argue that the estimated penetrance of 0.45% (95% CI 0.02%, 9.35%) calculated by leveraging the gnomAD (Lek et al., 2016) population data indicate that T201S is at most a low-risk gene variant for CJD. If we arbitrarily consider a central estimate of 10% or higher as the clinically signi
-
In the largest postmortem study of
2023-08-30

In the largest postmortem study of 3618 autopsied individuals, almost 75% of the individuals without Aβ pathology already harbored cortical NFT pathology mostly confined to the medial temporal regions (Murray et al., 2015). In Braak's study of 2366 autopsied individuals (Braak and Del Tredici, 2014)
-
Compelling evidence now indicates that DR is a
2023-08-30

Compelling evidence now indicates that DR is a multifactorial disease that involves chronic inflammation at every stage, from initiation to progression and eventually to ischemia and NV [6,7]. Data from animal studies suggest that leukocyte-endothelial cell adhesion and entrapment (leukostasis) are
-
Flavonoids protein interactions studies play a substantial p
2023-08-30

Flavonoids-protein interactions studies play a substantial part in the hunt for novel molecules which are to interact with a selected disease-relevant target [35]. The mode of potential interaction gives information about the flavonoid effectiveness and selectivity. Lately, possible target molecules
-
AKT activity is also self
2023-08-30

AKT activity is also self-limiting through its substrate GSK3β; the kinase activity of which is negatively regulated by AKT phosphorylation (Fig. 3; Li, Liu, & Gao, 2009). GSK3β activation results in phosphorylation and subsequent ubiquitin mediated degradation of PHLPP (Li et al., 2009). AKT activa
-
Silk which is a mixture of
2023-08-29

Silk, which is a mixture of mainly SF and sericin, has an extensive history in clinical application as a suture material. Unwanted immune reactions to silk sutures observed early on in their application were assigned to the presence of sericin. However, in vitro and in vivo evaluations of pure SF fi
-
A correlation analysis was performed to investigate a possib
2023-08-29

A correlation analysis was performed to investigate a possible relationship between serum resistin levels and MG-ADL. We observed a significant relationship between serum resistin levels and MG-ADL scores in AChR-GMG-positive cases (r=0.285, p=0.032; Fig. 1C). There were also significant correlation
-
Deazaneplanocin receptor Previously several genes such as cy
2023-08-29

Previously, several genes such as cytokine (Lyu and Park, 2007), cell motility-associated genes (Schotterl et al., 2017), transforming growth factor-β (TGF-β), TGF-β receptor II which is a cell surface receptor with serine/threonine kinase activity (Jiang et al., 2014, Schotterl et al., 2017), cell
-
Physiological total plasma LPA levels are normally less than
2023-08-29

Physiological total plasma LPA levels are normally less than 1μM in healthy subjects. LPA levels have been reported to be increased in malignant effusions or plasma in cancer patients [20]. In addition, increasing ATX activity detected in healthy pregnant women in the third trimester of pregnancy ex
-
br Mechanism of action In general the main
2023-08-29

Mechanism of action In general, the main targets for antifungal drug development are cell wall polymer (glucans, chitin, mannoproteins), cell membrane (especially ergosterol) biosynthesis, DNA and protein synthesis (topoisomerases, nucleases, elongation factors and myristoylation), and signal tra
-
br Future directions outlook Peptide based
2023-08-29

Future directions-outlook Peptide-based macrocycles are among the privileged scaffolds in antibiotic drug discovery. Many compounds were discovered by natural product screening and developed unchanged, or as semi-synthetic derivatizations. Since the golden age of antibiotic discovery (1940s-mid 1
-
Finally intracrine androgen synthesis metabolism
2023-08-29

Finally, intracrine androgen synthesis/metabolism can be activated thus allowing Tunicamycin to bypass the low levels of androgens in the circulation by producing androgens themselves (Cai and Balk, 2011, Rahman et al., 2004). Moreover, changes in AR co-regulators like the overexpression of steroid
-
Mouse iPSC Chemical Reprogramming Cocktails Kit plus Althoug
2023-08-29

Although mature fibrils formed from Aβ Mouse iPSC Chemical Reprogramming Cocktails Kit plus have long been thought to be the main neurodegenerative agents in AD, recent evidence suggests that soluble multimers of these pathogenic proteins, referred to here as “oligomers,” may initiate the synaptic
-
br Introduction There are greater than five million American
2023-08-29

Introduction There are greater than five million Americans living with Alzheimer's dementia and more than 35 million people worldwide [1], and without a way to stop or slow the progression, there will be nearly a tripling of individuals affected by 2050 (13.8 million) [1]. The urgency to develop
-
8-Methoxypsoralen synthesis br Development of lorlatinib fro
2023-08-29

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
15660 records 287/1044 page Previous Next First page 上5页 286287288289290 下5页 Last page